{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:01:28Z","timestamp":1776060088904,"version":"3.50.1"},"reference-count":27,"publisher":"Korean Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["C-2023-0040"],"award-info":[{"award-number":["C-2023-0040"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT","doi-asserted-by":"crossref","award":["RS-2023-00261820"],"award-info":[{"award-number":["RS-2023-00261820"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-22852968"],"award-info":[{"award-number":["RS-2025-22852968"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:p>PurposeLimited treatment options exist for patients with metastatic castration-resistant prostate cancer (mCRPC) after the failure of taxane-based chemotherapy and novel hormonal therapy. Here, we report the safety and efficacy of ifosfamide and mesna in patients with mCRPC after the failure of taxane-based chemotherapy and novel hormonal therapy (NCT06236789).Materials and MethodsPatients with histologically confirmed prostate cancer who had failed taxane-based chemotherapy and novel hormonal therapy received ifosfamide 2,500 mg\/m2 and mesna 1,500 mg\/m2 on days 1\u20133, repeated every 21 days. Safety, objective response rate, disease control rate, reduction in serum prostate-specific antigen (PSA) concentration by &gt;50% (PSA50) or &gt;90% (PSA90), radiographic progression-free survival (rPFS), and overall survival (OS) were analyzed.ResultsA total of 47 patients with mCRPC were included in the study. The median number of lines of treatment was 5 (range, 3 to 7). All patients were previously administered docetaxel and novel hormonal therapies including abiraterone (51.1%) and\/or enzalutamide (61.7%). Thirty-eight patients (80.9%) were administered cabazitaxel. The objective response and disease control rates were 21.3% and 80.9%, respectively. PSA50 and PSA90 were achieved in 31.9% and 10.6%, respectively. During a median follow-up duration of 54.3 months, rPFS and OS were 5.0 and 9.0 months, respectively. All the patients experienced treatment-related adverse events of any grades; however, no new safety signs were detected. Genomic biomarker analysis revealed that alterations in the TP53 pathway were associated with inferior rPFS and OS.ConclusionIfosfamide and mesna showed appreciable efficacy and manageable safety profiles in heavily treated patients with mCRPC.<\/jats:p>","DOI":"10.4143\/crt.2025.155","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:52:51Z","timestamp":1749419571000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Ifosfamide and Mesna in Metastatic Castration-Resistant Prostate Cancer after Taxane-Based Chemotherapy and Novel Hormonal Therapy Failure"],"prefix":"10.4143","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-8501","authenticated-orcid":true,"given":"Chang Gon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5157-5063","authenticated-orcid":true,"given":"Yeo Gyeong","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-7658","authenticated-orcid":true,"given":"Jongjin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-4553","authenticated-orcid":true,"given":"Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hoon","family":"Beom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Deuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Kyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Sik","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunho","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongsoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daeseong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sil","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-4282","authenticated-orcid":true,"given":"Minsun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-7241","authenticated-orcid":true,"given":"Sang Joon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7248"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00978-z"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.04.010"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.4008"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1996.14.6.1756"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.033"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00233"},{"key":"ref11","first-page":"157","volume-title":"Management of patients with advanced prostate cancer: report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","author":"Gillessen","year":"2025"},{"key":"ref12","first-page":"368","volume-title":"Phase II evaluation of ifosfamide\/mesna in metastatic prostate cancer. A Southwest Oncology Group study","author":"Williamson","year":"1996"},{"key":"ref13","first-page":"177","volume-title":"A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC)","author":"Hervonen","year":"2002"},{"key":"ref14","first-page":"1288","volume-title":"NCCN Guidelines(R) insights: prostate cancer, version 1.2023","author":"Schaeffer","year":"2022"},{"key":"ref15","first-page":"263","volume-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","author":"Cornford","year":"2021"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61389-x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0518"},{"key":"ref19","first-page":"321","volume-title":"Oncogenic signaling pathways in the Cancer Genome Atlas","author":"Sanchez-Vega","year":"2018"},{"key":"ref20","first-page":"1011","volume-title":"The molecular taxonomy of primary prostate cancer","year":"2015"},{"key":"ref21","first-page":"1091","volume-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","author":"Sartor","year":"2021"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911206"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.06.4907"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010683"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1096"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100671"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0246-9"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.155","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:32:12Z","timestamp":1776058332000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2025.155","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2025-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}